These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 36918943)
1. An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma. Yao N; Jiang W; Wang Y; Song Q; Cao X; Zheng W; Zhang J Eur J Med Res; 2023 Mar; 28(1):123. PubMed ID: 36918943 [TBL] [Abstract][Full Text] [Related]
2. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma. Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062 [TBL] [Abstract][Full Text] [Related]
3. An Unfolded Protein Response-Related mRNA Signature Predicting the Survival and Therapeutic Effect of Hepatocellular Carcinoma. Su Z; Wang L; Chen X; Zhong X; Wang D; Wang J; Shao L; Chen G; Wu J Comb Chem High Throughput Screen; 2022; 25(12):2046-2058. PubMed ID: 35125080 [TBL] [Abstract][Full Text] [Related]
4. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response. Chen J; Chen X; Li T; Wang L; Lin G Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273 [TBL] [Abstract][Full Text] [Related]
5. Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma. Tang B; Zhang X; Yang X; Wang W; Li R; Liu Y Front Immunol; 2022; 13():1013248. PubMed ID: 36466855 [TBL] [Abstract][Full Text] [Related]
6. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma. Wang Y; Song F; Zhang X; Yang C Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359 [TBL] [Abstract][Full Text] [Related]
7. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma. Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X Front Immunol; 2023; 14():1218661. PubMed ID: 37662906 [TBL] [Abstract][Full Text] [Related]
8. Exploration and validation of a combined Hypoxia and m6A/m5C/m1A regulated gene signature for prognosis prediction of liver cancer. Ren M; Fan B; Cao G; Zong R; Feng L; Sun H BMC Genomics; 2023 Dec; 24(1):776. PubMed ID: 38097948 [TBL] [Abstract][Full Text] [Related]
9. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma. Luo Y; Liu H; Fu H; Ding GS; Teng F Front Immunol; 2022; 13():974377. PubMed ID: 36458010 [TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis. Yan Z; He M; He L; Wei L; Zhang Y Front Immunol; 2021; 12():723271. PubMed ID: 34925311 [TBL] [Abstract][Full Text] [Related]
11. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes. Gu X; Guan J; Xu J; Zheng Q; Chen C; Yang Q; Huang C; Wang G; Zhou H; Chen Z; Zhu H J Transl Med; 2021 Jan; 19(1):26. PubMed ID: 33407546 [TBL] [Abstract][Full Text] [Related]
12. A Pyroptosis-Based Prognostic Model for Immune Microenvironment Estimation of Hepatocellular Carcinoma. Chen Z; Zou Y; Zhang Y; Chen Z; Wu F; Jin H; Shi N Dis Markers; 2022; 2022():8109771. PubMed ID: 35047095 [TBL] [Abstract][Full Text] [Related]
13. Histamine-related genes participate in the establishment of an immunosuppressive microenvironment and impact the immunotherapy response in hepatocellular carcinoma. Zhang X; Zheng P; Meng B; Zhuang H; Lu B; Yao J; Han F; Luo S Clin Exp Med; 2024 Jun; 24(1):129. PubMed ID: 38884870 [TBL] [Abstract][Full Text] [Related]
14. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma. Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R Front Immunol; 2022; 13():990790. PubMed ID: 36248822 [TBL] [Abstract][Full Text] [Related]
15. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma. Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595 [TBL] [Abstract][Full Text] [Related]
16. Signature construction and molecular subtype identification based on immune-related genes for better prediction of prognosis in hepatocellular carcinoma. Sun L; Wu Z; Dong C; Yu S; Huang H; Chen Z; Wu Z; Yin X BMC Med Genomics; 2023 Jun; 16(1):130. PubMed ID: 37316840 [TBL] [Abstract][Full Text] [Related]
17. A signature based on neutrophil extracellular trap-related genes for the assessment of prognosis, immunoinfiltration, mutation and therapeutic response in hepatocellular carcinoma. Wang L; Wang Q; Li Y; Qi X; Fan X J Gene Med; 2024 Jan; 26(1):e3588. PubMed ID: 37715643 [TBL] [Abstract][Full Text] [Related]
18. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma. Liu R; Liu Y; Zhang F; Wei J; Wu L Front Immunol; 2023; 14():1146411. PubMed ID: 37063920 [TBL] [Abstract][Full Text] [Related]
19. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma. Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201 [TBL] [Abstract][Full Text] [Related]
20. Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma. Tang Y; Guo C; Yang Z; Wang Y; Zhang Y; Wang D Front Immunol; 2022; 13():862527. PubMed ID: 35493471 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]